Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT ID: NCT07349498
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2026-01-01
2036-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
NCT07157670
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
NCT06386445
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
NCT06702111
Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
NCT03000244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing hematopoietic stem cell transplantation
Patients who undergo allogeneic hematopoietic stem cell transplantation at participating medical center.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient request to withdraw from the study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
UNKNOWN
First Affiliated Hospital of Zhejiang University
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
UNKNOWN
Xinqiao hospital of the third military medical university
UNKNOWN
The First Affiliated Hospital of Zhengzhou University
OTHER
Sun Yat-sen University Cancer Center, Sun Yat-sen University
UNKNOWN
Sichuan Provincial People's Hospital
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
First Affiliated Hospital of Xinjiang Medical University
OTHER
Chinese PLA General Hospital
OTHER
Peking University Shenzhen Hospital
OTHER
Peking University Third Hospital
OTHER
Peking University First Hospital
OTHER
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiao Hui Zhang
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Xinqiao hospital of the third military medical university
Chongqing, Chongqing Municipality, China
Sun Yat-sen University Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
First Affiliated Hospital Xi'an Jiaotong University
Xi'an, Shaanxi, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
Tianjin, Tianjin Municipality, China
First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dai Hong Liu
Role: primary
Yu Jun Dong
Role: primary
Hong Mei Jing
Role: primary
Xi Zhang
Role: primary
Yang Liang
Role: primary
Hong Yu Zhang
Role: primary
Sheng Jin Fan
Role: primary
Zhong Xing Jiang
Role: primary
Yi Cheng Zhang
Role: primary
Ling Hui Xia
Role: primary
Peng Cheng He
Role: primary
Xiao Bing Huang
Role: primary
Er Lie Jiang
Role: primary
Ming Jiang
Role: primary
Yi Luo
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-z232
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.